The Development of a Formulation of Topical Nanoemulgel of Eberconazole Nitrate

Abstract

Eberconazole is used to treat invasive Aspergillus and Candida infections, as well as fungal infections caused by Scedosporium and Fusarium species, which can occur in immunocompromised patients. It is also used to treat oropharyngeal candidiasis (OPC), including OPC unresponsive to itraconazole and/or fluconazole. It is also used to treat invasive infections of Candida, Mucor and Aspergillus species in severely immunocompromised patients. Clinical evidence of its usefulness in the treatment of invasive disease (fusariosis) caused by Fusarium species is limited. It appears to be useful in a murine model of naegleriasis. Antifungal therapy is one of the most effective mechanisms for eradicating a fungal infection to improve quality of life. Systemic treatment is usually indicated for nail infections, extensive skin infections, or those that have not responded to topical treatment. Traditional topical dosage forms cannot maintain or control drug transport on the skin for a long time, so they need longer treatment or must be supplemented with oral treatment. Fungal infections require repeated use of conventional dosage forms over a longer period of time. The emulsifier would facilitate long-term contact of the drug with the skin, and it also has the ability to change the properties of the skin, which improves the local treatment of skin fungal diseases. The strategy is to formulate a drug-loaded Nanoemulgel, which regulates the release of the drug on the skin surface within 24 hours.